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Human embryonic stem (ES) cells were first isolated from the 
human embryo in 1998, sparking the hotly debated, controversial 
field of stem cell research. The controversy arose as these cells can 
only be derived from fertilised human embryos at the blastocyst 
stage, resulting in destruction of the embryo. Like the cells of the 
early embryo, ES cells can differentiate into any cell type or tissue – a 
property termed pluripotency. They are therefore seen by many as 
the ‘magic bullet’ because they have the potential to regenerate cells, 
tissues or organs to treat disease.
In consequence of the ethical difficulties of obtaining fertilised 
human eggs, numerous ES cell lines have been created. The primary 
cells for these lines were obtained from surplus IVF embryos with full, 
informed consent. They have since been perpetuated in sterile culture 
and are commercially available. Basic research has proven their ability 
to differentiate into a multitude of cell types. Legislation is struggling 
to keep pace with ES cell research, which has been hampered by 
ethical and political pressure, predominantly in countries with some 
form of stem cell legislation.
Google ‘stem cell therapy’ and you will be confronted with a 
plethora of companies across the world offering to cure disease. 
The vast majority of these companies – most exist in countries with 
limited or no regulation on stem cell use – claim to cure disease 
simply via injection of the cells. There are only anecdotal data, and 
no hard scientific evidence, to substantiate their claims. Stem cells 
are mitotically hyperactive and have been shown to form teratomas 
following injection into mice – a property that has ultimately led to 
the death of some patients hoping for a miracle cure.1
Since the isolation of human ES cells, 2 less controversial stem 
cell types have been discovered: adult stem (AS) cells and induced 
pluripotent stem (iPS) cells. AS cells are not embryo-derived, but rather 
found within the tissues of the juvenile and adult body. Unlike ES 
cells, AS cell potency is restricted to a particular lineage, and is termed 
multipotency, e.g. lung AS cells are able to develop into several lung 
cell types, but not into other cell types. AS cells are few in number and, 
while some are relatively easy to harvest – such as those residing in the 
bone marrow, blood, skin, umbilical cord and muscle – those found in 
the brain or heart, for example, are difficult to obtain.
In 2006, scientists demonstrated a major breakthrough in stem 
cell research: they could re-programme normal somatic cells to a 
pluripotent ES-like state by introducing – very surprisingly – just 
a handful of re-programming genes. These cells (iPS cells) have 
enormous potential: they have been shown to differentiate into 
many different cell types,2 while obviating the ethical and harvesting 
drawbacks of ES and AS cells respectively. While the discovery of 
iPS cells is exciting, these are early days and there are no registered 
trials using these cells in patients. The safety of their use has not 
been proven unequivocally and there are concerns that these ‘old’ 
re-programmed somatic cells may not behave identically to their 
‘young’ ES cell counterparts.
Despite the perception that stem cells can miraculously cure 
disease, there are currently only 3 733 registered trials using forms 
of ES, AS and iPS cells (not all involving patients), according to 
ClinicalTrials.gov, a database of federally and privately funded 
clinical trials that are being conducted across 178 countries.3 
Only 3 of these registered trials are using ES cells and all are, as 
yet, without data to substantiate therapeutic success. The trials are 
privately funded by biotechnology companies in the USA, and do not 
involve injection of ES cells but rather the use of ES cell lines that have 
been induced to differentiate into particular cell types. The world’s 
first ES cell clinical trial was given Food and Drug Administration 
clearance in 2009. It involves the injection of ES cells, directed to an 
oligodendrocyte precursor cell lineage, into 10 patients with acute 
spinal cord injury within 10 days of injury.4,5 The trial has not been 
without controversy; it was initially halted, but has since resumed.6 
The remaining 2 trials have just begun to determine the effects of 
sub-retinal injection of ES cell-derived retinal pigment epithelial cells 
in patients with various forms of macular degeneration.
There has been more therapeutic success with AS cells. Indeed, 
doctors have been performing bone marrow transplants for decades 
to treat leukaemia, multiple myeloma and lymphoma, with the 
success of these transplants now known to be due to the presence 
of haematopoietic stem cells in the bone marrow, which are capable 
of differentiating into any blood cell type. The bone marrow also 
contains mesenchymal stem (MS) cells, which can differentiate 
into bone, cartilage, fat, cardiomyocytes and neural cells. MS cells 
can also be isolated from adipose, umbilical or muscle tissue, and 
then perpetuated ex vivo before autologous cells are selected and 
re-introduced into the patient. Such MS cell transplantation has 
showed varied degrees of success in humans, raising debates about 
the safety thereof.7-9 Nevertheless, there are almost 200 clinical trials 
using MS cells registered on ClinicalTrials.gov, with the vast majority 
in China or Korea.3
In summary, there is no doubt that stem cells, in all forms, have 
enormous potential to benefit the patient. The medical reality is 
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that their efficacy and safety in patients has not been established 
unequivocally.
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